Weight Loss Clinic Near Me: Semaglutide, GLP-1

Weight-loss clinics near you: semaglutide and tirzepatide

A GLP-1 weight-loss clinic is a medical practice that prescribes semaglutide (Wegovy) or tirzepatide (Zepbound), usually within a supervised program. FDA approved Wegovy for chronic weight management on June 4, 2021 and Zepbound in November 2023. Many clinics also offer compounded versions, which FDA stresses are not FDA-approved and haven’t been reviewed for safety, effectiveness or quality.

Virtual Care Atlas lists 2837 clinics whose own websites list GLP-1 & medical weight loss, and 1443 of them mention telehealth. Checked October 19, 2026.

GLP-1 weight-loss clinics per state
State	Clinics	Telehealth
Texas	319	203
Florida	264	154
California	189	80
Arizona	124	65
Tennessee	120	61
North Carolina	98	54
Nevada	82	40
Ohio	82	44
Georgia	78	45
Colorado	77	38
Virginia	76	34
Maryland	71	45
New York	65	33
South Carolina	65	30
Illinois	63	28
Oklahoma	62	24
Kentucky	58	20
Washington	58	32
Missouri	53	22
Wisconsin	53	22
Louisiana	49	20
Pennsylvania	48	33
Alabama	42	19
Kansas	42	15
Connecticut	41	25
New Jersey	40	16
Indiana	36	21
Utah	36	15
Nebraska	33	14
New Mexico	33	12
Michigan	32	16
Oregon	30	15
Idaho	29	18
Minnesota	29	11
Massachusetts	28	18
Rhode Island	25	12
New Hampshire	20	7
Montana	19	6
South Dakota	18	9
Alaska	17	7
Iowa	17	7
Delaware	16	6
Hawaii	16	6
North Dakota	16	4
Maine	15	9
Arkansas	14	9
District of Columbia	14	7
Mississippi	9	6
West Virginia	6	3
Vermont	5	1
Wyoming	5	2

State

Clinics

Telehealth

Texas

319

203

Florida

264

154

189

124

120

By Virtual Care Atlas Editorial Team · Updated October 19, 2026 · Editorial review: Virtual Care Atlas Editorial Team, fact-checked against the cited sources (not a clinical review) · How we verify

What a GLP-1 weight-loss clinic does

GLP-1 receptor agonists mimic a gut hormone involved in appetite regulation. For weight management, the two medications people search for most are semaglutide and tirzepatide (tirzepatide also acts on the GIP receptor). A typical clinic program includes an intake visit, lab work, a prescription, follow-up visits as doses are adjusted, and often nutrition or activity coaching.

The clinics listed here range from dedicated medical weight-loss practices to primary care, hormone and men’s health clinics, med spas with a medical director, and telehealth-first practices with a local office.

FDA-approved vs. compounded GLP-1 medications

This is the distinction that matters most when you compare clinics.

FDA-approved products. FDA approved Wegovy (semaglutide) injection for chronic weight management on June 4, 2021, for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition, alongside a reduced-calorie diet and more physical activity. FDA approved Zepbound (tirzepatide) for chronic weight management in November 2023. Ozempic (semaglutide) and Mounjaro (tirzepatide) are approved for type 2 diabetes.

Compounded versions. Many clinics offer compounded semaglutide or tirzepatide made by compounding pharmacies. FDA’s position, in its own words, is that compounded drugs “are not FDA approved”, so the agency doesn’t review them for safety, effectiveness or quality before they’re marketed. FDA recommends that compounded drugs be used only for patients whose medical needs can’t be met by an FDA-approved drug. It has also raised specific concerns:

Multiple-dose vials. FDA generally recommends using multiple-dose vials of sterile medication within 28 days of first use, because the risk of contamination rises after that.
Shipping temperature. Injectable GLP-1s need refrigeration. FDA advises not using a product that arrives warm or without enough refrigeration.
Retatrutide and cagrilintide. FDA says they cannot be used in compounding under federal law. It has warned telehealth companies for marketing retatrutide.

What the pivotal trials reported

These are average results from large randomized trials. They aren’t predictions or recommendations for anyone.

Trial	Medication	Duration	Mean weight change	Placebo
STEP 1 (NEJM 2021)	Semaglutide, once weekly	68 weeks	−14.9%	−2.4%
SURMOUNT-1 (NEJM 2022)	Tirzepatide, three doses	72 weeks	−15.0% / −19.5% / −20.9%	−3.1%

Both trials enrolled adults with obesity or overweight and included lifestyle support in every arm. Side effects, mainly gastrointestinal, led some participants to stop treatment. Ask a prescriber how the evidence applies to you.

Telehealth red flags FDA lists

FDA’s consumer guidance suggests caution if a company:

Claims its compounded drug is the same as an FDA-approved drug.
Offers deep discounts or prices that seem too good to be true.
Sends medicine that looks different from what you got before, or arrives damaged or without instructions.
Doesn’t require a screening and a prescription by a licensed doctor.
Doesn’t have a licensed doctor available to answer questions after you receive the medication.

How do I compare GLP-1 clinics?

Ask which product you’d receive: brand-name (FDA-approved) or compounded. If compounded, ask for the pharmacy’s name.
Confirm the prescriber’s license with your state board, and confirm they can treat patients in your state if it’s telehealth.
Ask what’s included: labs, visit frequency, dose-adjustment check-ins, and who you contact about side effects.
Get an itemized price in writing. Programs are priced as memberships, per-visit fees, medication fees, or bundles.
Ask about insurance. Brand-name products may be covered for some patients; compounded products usually aren’t.

How this list is built

We found clinics through public Google Maps listings in each metro. We kept a clinic only if its own website says it offers medical weight loss or names GLP-1 medications, either repeatedly or on a dedicated page. Each listing shows the medication names we found and links to the page. We checked phone and address against the clinic’s site and, where we could, the federal NPI Registry. No clinic pays to be listed. See our methodology.

Frequently asked questions

Is compounded semaglutide the same as Wegovy or Ozempic?

No. FDA states that compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before they are marketed. FDA lists a company claiming its compounded drug is the same as an FDA-approved drug as a red flag.

What did the main trials of semaglutide and tirzepatide for weight find?

In the STEP 1 trial (NEJM, 2021), adults without diabetes taking once-weekly semaglutide 2.4 mg had a mean body-weight change of −14.9% at 68 weeks, compared with −2.4% on placebo. In SURMOUNT-1 (NEJM, 2022), mean change at 72 weeks was −15.0%, −19.5% and −20.9% across the three tirzepatide doses, versus −3.1% on placebo. These are trial averages alongside diet and activity support, not predictions for any individual.

How does Virtual Care Atlas decide a clinic offers GLP-1 weight loss?

The clinic's own website must say it offers medical weight loss, GLP-1 medication, semaglutide or tirzepatide, either more than once or on a dedicated page. We show the medication names we found on the clinic's site and link to the page where we found them.

Can I start a GLP-1 program by telehealth?

Many clinics in this directory say they offer telehealth or virtual visits. A prescriber generally needs to be licensed in the state where you are. FDA also suggests watching for telehealth red flags, such as no screening or prescription by a licensed doctor, or prices that seem too good to be true.

Can clinics compound retatrutide?

No. FDA states that retatrutide and cagrilintide cannot be used in compounding under federal law, and that they are not components of FDA-approved drugs.